This VJHemOnc podcast highlights key AL amyloidosis updates from ASH 2025. Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, discusses a newly validated staging system defining ultra-high-risk disease in the daratumumab era.

Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, presents Phase II AQUARIUS data (NCT05250973) on daratumumab-VCd dosing and Phase I etentamig results (NCT06158854) in relapsed or refractory AL amyloidosis. Heather Landau, MD, Memorial Sloan Kettering Cancer Center, New York, NY, reviews early NEXICART-2 findings (NCT06097832) with BCMA-directed CAR T-cell therapy, Andrew Staron, MD, Boston Medical Center, Boston, MA, discusses sustained MRD negativity, and Matthew Rees, MD, St. Vincent’s Hospital, Melbourne, Australia, shares real-world BCMA-directed CAR T-cell and bispecific data.